G

Galmed Pharmaceuticals Ltd

D
GLMD
USD
0
(0%)
Market Closed
2,445.00
Volume
-1.29
EPS
-
Div Yield
-0.289272
P/E
4,656,605.28
Market Cap
Today
-6.9277%
1 Week
-7.485%
1 Month
-26.253%
6 Months
-37.195%
12 Months
-38.690%
Year To Date
-42.381%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
L
LIVN
0.42
(0.8146%)
USD
B
BGNE
4.44
(2.1924%)
USD
X
XENE
0.76
(1.6908%)
USD
R
RIGL
0.93
(6.405%)
USD
M
MYOV
(%)
USD
X
XNCR
0.52
(2.2907%)
USD
A
ACAD
1.42
(8.993%)
USD
F
FGEN
0.0027
(0.8727%)
USD
S
SSNC
0.4
(0.539%)
USD
E
EGRX
(%)
USD
J
JAZZ
7.635
(6.8528%)
USD
C
CTMX
-0.0026
(-0.2594%)
USD
N
NBRV
0.04
(2.8369%)
USD
JNJ
JNJ
-2.8
(-1.755%)
USD
A
AMRN
-0.0379
(-6.1506%)
USD

Title:
Galmed Pharmaceuticals Ltd

Sector:
Healthcare
Industry:
Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Do you need help or have a question?
Contact Us